��ɫAV Macau

Manufacturing Plant

Established in 1986, the site was first approved by the FDA in 1987 and is regularly inspected.

��ɫAV Macau was��established in 1986 and has since been upgraded��to��boost production capacity as well as to install waste water treatment facilities. The plant was first approved by the FDA in 1987 and is regularly inspected. The plant holds a GMP Certificate issued by Infarmed, the Portuguese Health Authority.

With a total reactor capacity of approximately 100m3, ��ɫAV Macau produces both generic and custom synthesis products. The plant benefits from its proximity to the People’s Republic of China for the supply of raw materials.

Area of Focused Expertise

The site has leading capabilities and physical assets in the following areas:

Cryogenic (Volume 6000L, Temperature Range -65 to 140ºC)
Hydrogenation (Volume 600L to 6000L, Pressure Rating 10 to 20bar)
Tetracycline and Macrolide chemistry

For details about production equipment – click here

Operations

The Macau plant operates 24 hours a day 7 days a week.
Quality Control labs supports production 24 hours a day 7 days a week.
Plant maintenance shutdown period takes place for 3 to 4 weeks in August.

Certifications

The site is certified in accordance with the ISO9001; ISO14001 and OHSAS18001.

��

��
��

For inquiries about ��ɫAV Macau, kindly fill the form below.

News

Lisbon, Portugal – ��ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ��ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ��ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ��ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ��ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ��ɫAV’s sustainability ambitions. ��ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating. Learn more about Science Based-Targets

News

��ɫAV commitment to setting SBTs in line with the Paris Agreement

��ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

Following the creation of offices in Shanghai and Beijing, ��ɫAV is pleased to announce the launch of its new website in Mandarin. This dedicated platform will enhance ��ɫAV´s presence in China, offering tailored contents to better serve customers in this important market. The new site will provide comprehensive information about ��ɫAV´s products and services, ensuring that Chinese clients have easier access to the innovative solutions and support that ��ɫAV is renowned for worldwide. “The launch of the ��ɫAV Chinese website underscores our commitment to customers in China,” said Ms. Jackie Liu, Country Head, China. “By delivering localized content and support, we aim to foster stronger partnerships and drive mutual growth in this market. Our team of experts is fully committed to understanding and addressing our clients´ unique challenges with agility and precision.” Visit us at www.hovione.com.cn

News

��ɫAV is closer to its customers with a new website in Mandarin

��ɫAV launches new website for the Chinese Market

Jun 14, 2024

��ɫAV Macau was recently awarded the Medal of Merit for Industrial and Commercial Excellence by the Government of Macau, a Special Administrative Region of the People´s Republic of China. This prestigious award recognizes the company's nearly 40 years of outstanding contribution to the pharmaceutical industry in Macau. Eddy Leong, Site Manager of ��ɫAV Macau, accepted this prestigious Medal on behalf of ��ɫAV at the ceremony held in Macau. Eddy Leong expressed his gratitude for the award and emphasized the company's commitment to working with partner organizations to create rewarding career opportunities in life sciences. Read this press release to learn more about the Medal of Merit awarded by ��ɫAV. If you would like to explore our open opportunities in ��ɫAV Macau, please visit our Careers Website.

News

Exciting News Alert from ��ɫAV in Macau

��ɫAV Macau awarded by the Government of Macau at a Ceremony held in Macau

Jan 19, 2024

Manufacturing Plant

Address

��ɫAV PharmaScience Ltd
Estrada Coronel Nicolau de Mesquita
Taipa
Macau
Tel: +853 2882 7544
Fax: +853 2882 7714
e-mail: infohm@hovione.com
DUNS Nr: 854974342��
Location:��

View all details

Browser not supported

��ɫAV Macau

News

��ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

��ɫAV launches new website for the Chinese Market

��ɫAV Macau awarded by the Government of Macau at a Ceremony held in Macau

Other Locations